An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Trial Profile

An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Olumacostat glasaretil (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Acronyms CLARITUDE
  • Sponsors Dermira
  • Most Recent Events

    • 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Oct 2017 According to a Dermira media release, positive results from CLAREOS-1 and CLAREOS-2, the completion of CLARITUDE and other registration-enabling studies are required to support a potential New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for olumacostat glasaretil.
    • 20 Apr 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top